Q219 saw marginal revenue growth amid single-injection momentum and competitive pricing pressure

The numbers are in and now that we are in the second quarter of 2019, the US Joint Fluid market seems to be getting off its slow-ish start of the year, gaining some momentum with the single-injection segment pushing the aggregate total revenue into positive growth, according to the recently published SmartTRAK Financial Dashboard. This, despite relentless and fierce pricing competition in the multi-injection arena. 

Among the many topics covered in the Q219 US Joint Fluid Market Recap* are:

Revenues down again, competitive pricing pressures remain, market is under FDA scrutiny

After a sluggish start of the year, the US Joint Fluid market gained steam during the quarter as demand and volumes picked up in several market segments in spite of intense competitive pricing pressures. Revenues were within SmartTRAK’s projected range with a marginal decline of -0.3% YoY according to the recently published SmartTRAK Financial Dashboard.

For Q119, the 3-injection segment accounted for 44.6%  of the US Joint Fluid market, followed by single-injection products at 41.5%, the 5-injection segment at 12.9% and rounding up the market with the 2-injection segment at 1.1%, according to SmartTRAK Financial Dashboard results. The single-injection segment showed good recovery from last year driven by increased adoption of newer products and/or sales expansion measures by some suppliers. The 3-injection segment was down in the low single digits during Q119 owing to continued and fierce pricing competition. The 5-injection segment showed no reprieve from its downward trend, declining...

Among the many topics covered in the Q119 US Joint Fluid Market Recap are:

Revenues down again, owing to intense competitive pricing pressures

Pricing pressure continued to negatively impact the US Joint Fluid market, which experienced a decline of -7.9% based on Q418 revenues according to SmartTRAK Financial Dashboard. While this market continued to see unit volume increases, ASPs experienced notable declines over the past four quarters as a result of several companies not listing ASPs to CMS, which fueled competitive pricing. Additionally, revenues were impacted by the Anthem non-coverage decision that took effect in Q118 and kept impacting suppliers over the course of the year...

Among the many topics covered in the Q418/FY18 Joint Fluid Market Recap:

Pricing pressure continues to dampen the US Joint Fluid market, which experienced a double-digit decline of -9.9% according to SmartTRAK's Financial Dashboard results. While the market continues to expand in terms of the number of patients treated, ASPs have steadily eroded over the past three quarters since the Anthem non-coverage decision kicked in earlier this year. Year-to-date, the US Joint Fluid market slowed significantly, posting negative growth according to SmartTRAK estimates...